Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1681227 | 0.76 | TDP1 (0.33) | SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL2066301 | 0.70 | — | — | |
| SCHEMBL14964964 | 0.63 | — | — | |
| SCHEMBL28166120 | 0.63 | — | — | |
| SCHEMBL3833595 | 0.62 | ADRB1 (0.39) | ALDH1A1 | |
| SCHEMBL4417431 | 0.60 | CYP1A2 (0.32) | MAPTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4417432 | 0.60 | CHKA (0.32) | SMN1; SMN2HPGDTDP1 | |
| SCHEMBL28232318 | 0.60 | — | — | |
| SCHEMBL2321070 | 0.58 | LMNA (0.36) | MAPTNPC1TP53RAB9AALDH1A1 | |
| SCHEMBL27834073 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103842030-A | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | HOFFMANN LA ROCHE | 2014-06-04 | — | — | CN | disclosed |